A second kindred has been identified which supports the previously reported location of DFNB9. Linkage has been established to markers closely linked to DFNB9 which is located on 2p22-p23. The hearing impaired individuals in this highly consanguineous kindred from Eastern Turkey have prelingual profound hearing loss which affects all frequencies. A genetic map of the 2p22-p23 region where DFNB9 resides was generated using marker genotypes available from the CEPH database. All markers were placed on this genetic map using a likelihood ratio criterion of 1000:1. This map suggests that the region for DFNB9 is less than 1.08 cM, 95% confidence interval (0-2.59 cM).
Introduction
Thus far, 16 autosomal recessive hearing loss genes (DFNB) have been localized, of which two have been isolated: the unconventional myosin VIIa gene for DFNB2 1, 2 and Connexin 26 3 for DFNB1. The hearing impaired individuals from kindreds which segregate known DFNB loci manifest prelingual profound hearing loss, with the exception of DNFB8 where hearing impaired individuals present with postlingual progressive hearing loss. Linkage has been reported for more than one family for the majority of the DFNB loci (DFNB1-4, DFNB7/11, DFNB8/10). 4 A second family with autosomal recessive neurosensory hearing loss that segregates DFNB9 is presented here. DFNB9 was previously mapped to 2p22-23 in a consanguineous family from Lebanon. 5 Linkage was established to markers closely linked to DFNB9 in this highly consanguineous kindred from Eastern Turkey.
Material and Methods

Auditory Tests
Informed consent was obtained from all study participants and from the parents of under-aged study participants. Puretone audiometry with air and bone conduction at 250, 500, Correspondence: Dr Suzanne M Leal, Laboratory of Statistical Genetics, 1230 York, Avenue, Box 192, New York, NY1000, 2000, 4000, and 8000 Hz was performed on all living pedigree members, except for individual VI.3 for whom auditory brain response (ABR) was performed due to her age of less than one year. In addition all individuals received an otoscopic examination.
Genotyping
Genomic DNA was extracted from 10 ml of blood using the QIAamp System Blood Kits from QUIAGEN. Amplification of the microsatellite markers was performed using standard methods previously described. 6 The primer sequences of the Genethon and CHLC markers: D2S144; D2S14; D2S158; D2S170; D2S171; D2S174; D2S305; D2S310; D2S365; D2S375; D2S405; D2S1325; D2S2144; D2S2263; and D2S2303 have been previously reported.
7,8
Linkage Analysis
Two-point lod scores were calculated using MLINK of the LINKAGE 5.1 computer program package. 9 The analysis was done under an autosomal recessive mode of inheritance, where the disease phenotype is fully penetrant with no phenocopies. The recombination fraction was assumed to be equal for males and females. The disease frequency was set to 0.0001. Since the disease frequency is unknown, linkage analysis was also carried out varying the disease frequency between 0.01 and 0.00001 in order to evaluate the effect of changing the allele frequencies on the lod score. The allele frequencies for the markers were assumed to be equal, since the true allele frequency for this population is unknown. To avoid obtaining a false positive result due to using a low allele frequency for a common allele, the linkage analysis was also carried out with the allele frequency doubled for the allele that segregates with the disease allele.
Since all the markers analyzed had not previously been placed on a single genetic map, a map was generated using publicly available genotype data from the CEPH database. 10 MultiMap and CRI-MAP were used to place the markers on a genetic map using a likelihood criterion of 1000:1.
11,12 The confidence interval for DFNB9 locus was calculated using the variance-covariance matrix, which was given by CILINK. Figure 1 illustrates a genetic map of the 2p22-p23 region where DFNB9 resides. Asterisks denote those markers for which there were no recombination events in the CEPH data. The relative order of these markers is unknown. Those markers which belong to the same linkage group but which could not be placed uniquely on the genetic map with a likelihood ratio of 1000:1 are mapped to intervals and are shown next to the map. It was previously reported that DFNB9 lies between D2S2303 and D2S174. 5 This genetic map suggests that this region is 1.08 cM, 95% confidence interval (0, 2.59 cM). Figure 2 shows a drawing of Turkey-21, the kindred segregating DFNB9. The hearing impaired individuals within this kindred have profound hearing loss affecting all frequencies with onset before the second year of life. This kindred supports the previously identified location of DFNB9. However, this kindred did not aid in the reduction of the genetic region for DNFB9; the disease haplotype for this kindred is over 17.5 cM. The results of the linkage analysis for all markers tested are shown in Figure 1 . The maximum lod scores and the recombination fraction at which each occurred are shown in parentheses next to each marker tested. A maximum lod score of 3.9 was obtained at recombination fraction 0.0 for marker D2S2263. When the allele frequency was doubled for the marker allele which segregated with the disease allele, the lod scores remained significant for markers D2S2663, D2S365, and D2S170. The results also stayed significant for these three marker loci when the disease allele frequency was varied between 0.01 and 0.00001.
Results and Discussion
Two additional consanguineous autosomal recessive NSHL kindreds from Western Turkey were genotyped for markers closely linked to DFNB9. Linkage was excluded to the genetic region for DFNB9 for each of these kindreds (data not shown).
Turkey-21 is the second kindred to be reported which segregates DFNB9. The members of this kindred originally come from Eastern Turkey, a region which is not geographically distant from Northern Lebanon, where the members of the first kindred reported to segregate DFNB9 reside. Only through additional study will the prevalence of DFNB9 be elucidated. A broader examination will show whether or not its occurrence is limited to this Middle Eastern geographic region.
